Best in Biotech 29 Apr 2025 Six biotech companies leading the charge in hemophilia treatment …on the market can only address one disease subtype because they work by replacing a specific clotting factor. Be Biopharma Technology: Engineered B cell medicines Lead hemophilia candidate: BE-101 Recent… April 29, 2025 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 12 Dec 2017 Grab the Tissues: Here are the 8 Biggest European Biotech Clinical Failures of 2017 …fresh start that is 2018 are fast approaching, so let’s get this over and done with: here are 2017’s biggest clinical disappointments. CureVac’s Prostate Cancer Candidate Misses Primary Endpoint The… December 12, 2017 - 7 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 25 Aug 2020 What Does Unity’s Phase II Fail Mean for European Anti-Aging Research? …has a different cellular target to that of Unity’s lead candidate, and Velabs’ candidates are antibody drugs instead of small molecules. Senolytx is branching out into developing senomorphic drugs —… August 25, 2020 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 1 Aug 2025 Oncolytic virus therapy for cancer: what’s been going on in 2025? …it in clinical trials, licensing deals, or candidates being awarded various regulatory designations. Table of contents Calidi Biotherapeutics’ oncolytic virus CLD-201 bags FDA fast track designation For instance, California-based Calidi… August 1, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 5 Sep 2024 Six biotech companies that could revolutionize obesity treatments …slash drug prices as more and more drugs enter the market. And so are Swiss multinational Roche’s clinical candidates including its once-daily weight loss pill that has shown promise in… September 5, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2017 Galapagos Cystic Fibrosis Drug Enters Phase I, Triggering €8.5M Payout …of a number of candidates that Galapagos and AbbVie are looking at to form a triple combination therapy. This particular candidate is a corrector drug, meaning it helps to restore… November 22, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jun 2020 AbbVie and Genmab Strike €3.4B Immuno-Oncology Megadeal …sales milestones. The two companies will jointly develop and commercialize three of Genmab’s anti-cancer antibody drugs, which are currently in phase I trials. Genmab’s antibody drugs — which are able… June 11, 2020 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
More News! 18 May 2017 Abcam Makes Final Payment in the Acquisition of an US Antibody Biotech Abcam has paid US-based AxioMx a final €4.5M milestone based on performance, completing an acquisition that totals €36.4M. Giant antibody maker Abcam, founded by star biotech entrepreneur Jonathan Milner and… May 18, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Mar 2017 Get Ready for One of the Biggest New Drug Approvals of the Year …such as those implicated in atopic dermatitis, asthma and allergies. The antibody represents the first drug targeting the IL-4/IL-13 pathways. The antibody is indicated for the treatment of moderate to… March 29, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 Jun 2023 Five biotech companies making a name for themselves in Vancouver …antibody therapy treatment for COVID-19, when, in 2021, bamlanivimab, used together with etesevimab, became the first monoclonal antibody medicine for COVID-19 to receive U.S. Food and Drug Administration (FDA) Emergency… June 30, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2022 Transcenta monoclonal antibody gets FDA clearance Transcenta Holding Limited says its TST004 humanized monoclonal antibody targeting MASP2, has received IND clearance from the U.S. Food and Drug Administration (FDA). MASP2, mannose-binding protein-associated serine protease 2, is… October 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Oct 2018 Innate’s Cancer Immunotherapy Combo Beats Standard Treatment Twofold …cancer patients that is very hard to treat. A checkpoint inhibitor antibody In the Phase II trial, Innate’s checkpoint inhibitor antibody was part of a combination therapy. While… October 22, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email